AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
Benzinga
MARCH 25, 2024
and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. NYSE: ABBV ) ("AbbVie") and Landos Biopharma, Inc. NX-13 and its bimodal MOA have the potential to provide a novel approach to the treatment of ulcerative colitis and Crohn's disease. NORTH CHICAGO, Ill. per share in cash upon closing, or approximately $137.5
Let's personalize your content